This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff. Twenty minutes a day, five days a week, ready by 6 a.m. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York ...
…
continue reading
محتوای ارائه شده توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !
با برنامه Player FM !
S6 Ep36: Biosimilars Business Roundup for August 2024—Podcast Edition
Manage episode 437477620 series 2161808
محتوای ارائه شده توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Show notes
1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024
2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars
4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
5. FDA Approves Biosimilar Enzeevu for Eye Conditions
6. Manitoba Adopts Biosimilar Switching Policy
7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline
2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars
4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
5. FDA Approves Biosimilar Enzeevu for Eye Conditions
6. Manitoba Adopts Biosimilar Switching Policy
7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline
157 قسمت
Manage episode 437477620 series 2161808
محتوای ارائه شده توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Show notes
1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024
2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars
4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
5. FDA Approves Biosimilar Enzeevu for Eye Conditions
6. Manitoba Adopts Biosimilar Switching Policy
7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline
2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars
4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
5. FDA Approves Biosimilar Enzeevu for Eye Conditions
6. Manitoba Adopts Biosimilar Switching Policy
7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline
157 قسمت
Todos los episodios
×به Player FM خوش آمدید!
Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.